Skanditek's subsidiary CMA Microdialysis AB to implement new share issue totaling SEK 70 million

Skanditek's subsidiary CMA Microdialysis AB to implement new share issue
totaling SEK 70 million

The Skanditek subsidiary CMA is implementing a private placement of new shares
amounting to SEK 56 million. The new issue will be directed at Investor Growth
Capital. Within a period of three years, CMA's Board of Directors will have an
opportunity to arrange an additional private placement aimed at Investor Growth
Capital in an amount of SEK 14 million. 

For further information, see the appended press release from CMA Microdialysis
AB or visit www.microdialysis.se

CMA will hold an Extraordinary General Meeting on Thursday, October 16, 2008.
Prior to the private placement, Skanditek's shareholding in CMA amounts to 77.95
percent. Following implementation of the private placement, amounting to SEK 56
million, Skanditek's shareholding in CMA will be reduced to 49.93 percent and
CMA will thus switch from being a Skanditek subsidiary to an associated company.



Stockholm, September 16, 2008 

SKANDITEK INDUSTRIFÖRVALTNING AB (publ) 



For further information, please contact: 

Patrik Tigerschiöld, President and CEO, 
telephone: +46-(0)8-614 00 20; e-mail:
patrik.tigerschiold@skanditek.semailto:patrik.tigerschiold@skanditek.se 


SKANDITEK is an industrial holding company with investments in Swedish
companies. The business concept is to generate sustainable and healthy value
growth by means of industrial management of operational companies. The portfolio
comprises nine investments in the electronics, bio/medical technology and
services sectors. The principal holdings are Bure Equity, MYDATA automation,
PartnerTech, Vitrolife and CMA. Skanditek is listed on the OMX Nordic Exchange.





Stockholm, September 16, 2008

CMA Microdialysis raises SEK 70 million in growth capital

CMA Microdialysis AB (“CMA”), a leading Swedish medical device company,
accelerates its growth agenda by raising SEK 70 million (approx USD 10.4
million) from Investor Growth Capital.

CMA is the pioneer and leader within organ diagnostics and tissue chemistry
monitoring. The company's medical devices are used in intensive care across the
globe to monitor biochemical processes in individual organs such as the brain,
liver and abdomen. The unique technology provides opportunities to detect
changes in organ chemistry, thereby predicting the onset of complications and
disease processes. The company was founded in 1984.

In response to the demands of modern intensive care for real-time and more
efficient blood glucose monitors, CMA was awarded a large grant from VINNOVA
(Swedish Governmental Agency for Innovation Systems) in 2007. The grant, in
combination with dedicated support from the major shareholder Skanditek
Industriförvaltning AB, has enabled the development of a new technical platform
offering the opportunity for real-time monitoring of blood glucose and other
metabolic markers.

“The aim of the growth capital is to accelerate our efforts to develop a new
real-time system for monitoring metabolic markers, including blood glucose. Our
vision is to offer real-time solutions that can streamline the many manual
routines of modern intensive care by delivering quicker and more accurate
clinical decisions.” says Philip Siberg, President and CEO of CMA.

Through a new shares issue, Investor Growth Capital, a subsidiary of Investor
AB, is initially investing SEK 56 million (approx USD 8.3 million) in CMA. The
board of CMA has the right to call for an additional SEK 14 million (approx USD
2.1 million) from IGC within three years. IGC will become the second largest
shareholder following Skanditek Industriförvaltning AB. 

The aim of the growth capital is to accelerate CMA's growth plans and to prepare
for a future international roll-out of the company's new technology platform. As
a part of the intensified growth agenda, CMA will simultaneously invest SEK 27.5
million (approx USD 4.1 million) in the affiliate company, Dipylon Medical AB. 


For more information, please contact:

Philip Siberg, CEO
CMA Microdialysis AB
Tel: +46-(0)70 790 6734
psi@microdialysis.se

About CMA Microdialysis AB
CMA Microdialysis is the leading company devoted to the development,
manufacturing and marketing of the Microdialysis technique. The company was
formed in 1984 and was the first company in the world to market Microdialysis
products and know-how. Consumables, instruments and computer software are sold
to universities, hospitals and pharmaceutical companies as unique tools for in
vivo sampling and diagnostics of organs and tissues. CMA has offices in Sweden,
the US and Germany, as well as distributors covering more than 40 countries. For
more information, see www.microdialysis.com

The information in this press release is of the type that Skanditek is obligated
to disclose in accordance with the Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for disclosure on
September 16, 2008 at 09.25 a.m. CET.